Targeting β-Arrestins in the Treatment of Psychiatric and Neurological Disorders Sharonda S. HarrisNikhil M. Urs Leading Article 02 March 2021 Pages: 253 - 264
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox–Gastaut Syndrome Simona LattanziEugen TrinkaFrancesco Brigo Systematic Review Open access 22 March 2021 Pages: 265 - 281
Psychotropic Drug-Induced Glaucoma: A Practical Guide to Diagnosis and Management Neeranjali S. JainClaire W. RuanRichard J. Symes Review Article 19 February 2021 Pages: 283 - 289
Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report Trisha ChakrabartyShane J. McInerneythe CAN-BIND Investigator Team Original Research Article 08 March 2021 Pages: 291 - 304
Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study Amichai PerlmanRachel GoldsteinMordechai Muszkat Original Research Article Open access 17 February 2021 Pages: 305 - 316
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies Anthony T. RederDiego CentonzeCarl de Moor Original Research Article Open access 20 March 2021 Pages: 317 - 330
First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat Rosa María AntonijoanJuan Manuel Ferrero-CafieroTamara Maes Original Research Article Open access 23 March 2021 Pages: 331 - 344